Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have been assigned a consensus rating of “Hold” from the twenty-eight ratings firms that are presently covering the firm, MarketBeat.com reports. Six analysts have rated the stock with a sell rating, thirteen have given a hold rating and nine have assigned a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $33.56.

Several equities analysts have recently weighed in on SRPT shares. Wedbush lifted their target price on shares of Sarepta Therapeutics from $32.00 to $34.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Guggenheim dropped their price target on shares of Sarepta Therapeutics from $22.00 to $19.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Mizuho upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $19.00 to $26.00 in a research report on Wednesday, November 5th. Barclays assumed coverage on shares of Sarepta Therapeutics in a research note on Wednesday, January 28th. They set an “equal weight” rating and a $20.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Sarepta Therapeutics in a research report on Monday, December 29th.

Sarepta Therapeutics Stock Down 4.0%

Sarepta Therapeutics stock opened at $16.76 on Monday. The firm has a market cap of $1.76 billion, a price-to-earnings ratio of -1.99, a price-to-earnings-growth ratio of 0.27 and a beta of 0.42. Sarepta Therapeutics has a 52 week low of $10.41 and a 52 week high of $108.48. The business’s 50-day moving average price is $20.43 and its 200 day moving average price is $20.22. The company has a quick ratio of 1.48, a current ratio of 2.32 and a debt-to-equity ratio of 0.73.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($2.71). Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. The company had revenue of $442.93 million during the quarter, compared to analyst estimates of $390.95 million. During the same period in the previous year, the firm posted $1.90 earnings per share. The company’s revenue was down 32.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Sarepta Therapeutics will post 2.67 earnings per share for the current year.

Insider Buying and Selling

In other Sarepta Therapeutics news, COO Ian Michael Estepan sold 13,187 shares of the firm’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $22.31, for a total value of $294,201.97. Following the sale, the chief operating officer directly owned 193,300 shares of the company’s stock, valued at approximately $4,312,523. This trade represents a 6.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Kestra Advisory Services LLC acquired a new stake in Sarepta Therapeutics in the 4th quarter valued at $25,000. iSAM Funds UK Ltd purchased a new position in Sarepta Therapeutics during the third quarter valued at $25,000. Ancora Advisors LLC grew its position in shares of Sarepta Therapeutics by 200.0% in the third quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,000 shares during the period. Byrne Asset Management LLC acquired a new stake in shares of Sarepta Therapeutics in the third quarter valued at about $33,000. Finally, Allworth Financial LP increased its stake in shares of Sarepta Therapeutics by 2,098.8% during the third quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 1,721 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

More Sarepta Therapeutics News

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Revenue beat estimates in Q4 ($442.9M vs. ~$391M consensus), which partially offsets earnings weakness and suggests underlying commercial traction outside the challenged product. Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates
• Positive Sentiment: Wells Fargo kept an “overweight” rating on SRPT, implying continued analyst conviction in the story despite lowering its price target to $38 (from $45), signaling potential upside from current levels. Wells Fargo Lowers Price Target
• Neutral Sentiment: Sarepta expanded non-market PR and community programs — opening applications for the Route 79 Duchenne scholarship — which supports brand and patient-community relations but is unlikely to move near-term valuation. Sarepta Announces Route 79 Scholarship
• Neutral Sentiment: Sarepta plans to present long-term and safety data at the upcoming MDA conference — data releases could be material but timing and contents are uncertain. Sarepta to Present Long-Term Data at MDA
• Negative Sentiment: Large Q4 EPS miss: reported EPS was far worse than consensus (reported loss −$3.58 vs. est. −$0.87), driven by a steep decline in ELEVIDYS sales and a wider net loss, increasing short-term revenue and margin uncertainty. Sarepta Q4 Earnings Report
• Negative Sentiment: CEO Douglas Ingram announced he will retire by year-end (or upon his replacement), introducing leadership transition risk at a sensitive time for product recovery and strategy execution. Reuters: Sarepta CEO Ingram to Retire
• Negative Sentiment: Institutional selling: AXQ Capital materially trimmed its SRPT stake (large percentage reduction), which can add selling pressure and signal reduced conviction among some holders. AXQ Capital Lowers Position in Sarepta

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.